Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early MRI response to certolizumab pegol in active rheumatoid arthritis
NL-OMON34044Phase 3Active, not recruiting
- Sponsor
- UCB
- Start
- Dec 2011
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by UCB. Primary endpoint: Change from baseline in OMERACT RAMRIS synovitis score at Week 16. Started Dec 2011; status: active, not recruiting.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON34044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34044.